Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting ...Middle East

NOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany, April 25, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Novaliq...

Hence then, the article about bausch lomb presents data from first pivotal phase 3 trial of investigational treatment nov03 perfluorohexyloctane at the american society of cataract and refractive surgery annual meeting was published today ( Monday 25/04/2022 - 02:09 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting )

Also on site :

• US trade with Southeast Asia and Taiwan surging despite Trump tariffs
• Will Trent's Erika Christensen On The Significance Of Angie Having A Girl, Her Engagement To Seth, And What Changes (And Doesn't) With Will
• Remember 2016? Panera Wants You to Relive It — One Broccoli Cheddar Bread Bowl at a Time